Most cancer drugs don’t actually kill cancer — they just slow it down.

In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, reveals why many FDA-approved cancer treatments are cytostatic, meaning they only halt tumor growth — not destroy it. The future, he says, is in cytotoxic precision oncology: treatments designed to actually kill cancer cells while sparing healthy ones.

Dr. Prato breaks down the crucial difference between managing and eliminating cancer, and explains why the immune system must be engaged for durable remissions. Using deep mapping tools like DNA, RNA, spatial biology, and immune profiling, Envita customizes therapies that combine precision targeting with immune activation — shifting the goal from “control” to “cure-driven remission.”

🎯 What You’ll Learn in This Episode:

• The real difference between cytostatic and cytotoxic drugs
• Why most new cancer drugs are designed to manage, not eliminate, disease
• How the immune system provides true cytotoxic killing power
• Why immunotherapy (PD-1s, NK cells) needs customization
• How deep mapping (DNA, RNA, spatial biology) reveals better treatment targets
• How Envita achieved up to 35x improved outcomes in late-stage patients*
  
  

📊 In published outcomes, precision oncology achieved up to 35x better responses and 43x improved quality of life by focusing on cytotoxic, immune-centered treatment algorithms.
*(See Outcomes Disclaimer Below)

“Managing cancer isn’t enough — it’s time to design care that actually kills it.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493

Patients don’t die of cancer alone — they die from waiting.

In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, exposes how the cancer system’s slow approvals, outdated guidelines, and insurance roadblocks cost patients precious time. Care delayed is care denied — and that’s why Dr. Prato and his team built a precision ecosystem to help patients access advanced, individualized care now.

Discover how N of one precision oncology eliminates delays by combining next-generation DNA/RNA sequencing, immune profiling, spatial biology, and molecular heat mapping to design treatments unique to every patient.

🎯 What You’ll Learn in This Episode:

• Why prior authorizations and step therapies delay lifesaving care
• How “population health” oncology ignores your personal biology
• The truth about drug pipelines designed to manage — not cure — cancer
• How precision mapping (DNA, RNA, immune, spatial) speeds effective treatment
• Why waiting on outdated clinical trial models costs lives

How patients see 35x better responses and 43x better quality of life using targeted, personalized care*

📊 In Envita’s published data, late-stage cancer patients achieved dramatically improved outcomes through precision-matched treatments — without the long delays of traditional oncology.*
*(See Outcomes Disclaimer Below)

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: https://www.envita.com

📞 Speak to a care coordinator: 866-830-4576

“Care delayed is care denied. Precision care saves time — and lives.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at: 

https://www.scirp.org/journal/paperinformation?paperid=132493

What if the best prostate cancer treatment doesn’t cut, burn, or destroy your vitality — yet still teaches your immune system to find and fight cancer throughout the body?

In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, explains how precision oncology and interventional radiology are redefining prostate cancer care. Instead of relying on radical surgery or radiation, Envita uses deep DNA/RNA sequencing, immune profiling, and 3D cone-beam imaging to guide minimally invasive, immune-centered procedures.

Dr. Prato discusses the risks of standard prostate surgery — including incontinence, erectile dysfunction, and long-term recurrence — and how precision targeting eliminates guesswork by treating the tumor directly and stimulating the immune system for long-term remission.

🎯 What You’ll Learn in This Episode:

• Why up to 50% of men experience PSA recurrence after prostate surgery

• How interventional oncology delivers treatment directly to the tumor site

• Why immune-based, precision care improves long-term outcomes

• The difference between radical surgery and image-guided microcatheter treatment

• How DNA, RNA, and spatial biology testing reveal cancer’s weak points

• Why deep mapping prevents recurrence and protects quality of life

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: https://www.envita.com

📞 Speak to a care coordinator: 866-830-4576

“The future of prostate cancer care is precise, personalized, and immune-centered.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at: 

https://www.scirp.org/journal/paperinformation?paperid=132493

What is the best treatment for advanced melanoma — and why do some therapies fail while others succeed?

In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, breaks down the future of melanoma care: deep mapping and immune-centered precision oncology. Using DNA, RNA, and spatial biology, Dr. Prato explains how mapping every pathway — not just BRAF mutations — gives doctors a full picture of the tumor’s environment, revealing why PD-1 inhibitors, BRAF/MEK drugs, and other standard therapies work for only a small group of patients.

The key to melanoma, he says, lies in natural killer (NK) cells. These immune cells, trained through AAIT (Autologous Adoptive Immunotherapy), can cross the blood-brain barrier and destroy tumor cells without the side effects of high-dose systemic drugs. By combining deep mapping, immune retraining, and microdosed precision therapies, Envita helps patients move from reactionary care to immune-guided treatment.

🎯 What You’ll Learn in This Episode:

• Why most standard melanoma treatments only help a small percentage of patients

• How DNA, RNA, and spatial biology mapping reveal hidden resistance pathways

• The difference between TIL therapy and AAIT (Autoglutid Adaptive Immunotherapy)

• How NK and dendritic cells are trained using DAMPs to target melanoma cells

• Why changing the tumor microenvironment is critical for immune response

• How AAIT avoids cytokine storms and side effects seen in other therapies

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: https://www.envita.com

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

 https://www.scirp.org/journal/paperinformation?paperid=132493

Repurposed drugs can be powerful in cancer care — but only when they’re matched to the right biology.

In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, explains how deep multi-omics testing (DNA, RNA, immune, and spatial biology) reveals whether agents like ivermectin, methylene blue, mebendazole, or fenbendazole actually fit your tumor’s molecular targets.

Many “alternative” treatments fail because they’re given blindly. Precision oncology replaces that guesswork by combining repurposed drugs, on-label therapies, and immunotherapy support into one guided plan designed for your unique cancer. Dr. Prato shows how these strategies are used at Envita to enhance drug delivery, minimize toxicity, and strengthen immune response.

🎯 What You’ll Learn in This Episode:

• Why repurposed drugs can help — but fail without precision targeting

• How DNA, RNA, and immune/spatial mapping identify the right off-label options

• When microdosing, compounding, or direct tumor delivery may improve results

• Why published studies are a starting point — not a one-size-fits-all guide

• How combining on-label and off-label medications improves outcomes safely

• Why Envita’s precision oncology achieved better responses and fewer side effects

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: https://www.envita.com

📞 Speak to a care coordinator: 866-830-4576

“Repurposed doesn’t mean random — it means targeted, tested, and personalized.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at: 

https://www.scirp.org/journal/paperinformation?paperid=132493

Cancer is not just a battle of the body — it’s also a battle of the heart and spirit.

In this deeply moving episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, explores how forgiveness, faith, and emotional peace are essential parts of the healing journey. Drawing from more than 25 years of walking with patients through their most challenging moments, Dr. Prato shares how releasing trauma, stress, and unforgiveness can restore strength to the immune system and open the door to physical and emotional recovery.

He explains the connection between chronic stress, immune suppression, and poor sleep, and how spiritual healing can help regulate the body’s natural rhythms. Through prayer, reflection, and breathwork grounded in faith, patients can reconnect with the peace of God that brings true rest and renewal.

🎯 What You’ll Learn in This Episode:

• How emotional wounds and unforgiveness suppress the immune system

• Why forgiveness is a decision that unlocks physical and spiritual healing

• Simple reflection and prayer practices that calm the body and mind

• How breathwork and scripture together create peace and relaxation

• The role of faith, love, and surrender in long-term healing

• How spiritual connection strengthens the will to recover

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: https://www.envita.com

📞 Speak to a care coordinator: 866-830-4576

“True healing begins when we forgive, surrender, and let peace in.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at: 

https://www.scirp.org/journal/paperinformation?paperid=132493

Imagine being told you’re cancer-free — twice — only for the cancer to come back a year later.

In this powerful episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, shares the true story of Emma, a breast cancer patient who followed every standard guideline and still faced a devastating recurrence. Despite surgery, chemo, and a “low concern” blood test, Emma’s cancer returned because her care relied on incomplete data and one-size-fits-all testing.

Dr. Prato explains how false reassurance from small genetic panels can leave critical pathways and immune signals undetected. He shows how precision oncology — using deep DNA/RNA sequencing, immune profiling, and spatial biology — reveals the full picture behind cancer recurrence. By combining this information with custom drug design, microdosed chemo, and interventional oncology, Envita helped Emma achieve remission safely and sustainably.

🎯 What You’ll Learn in This Episode:

• Why small blood tests can falsely reassure patients
  
  
• How most genetic panels miss key mutations and immune factors
  
  
• What deep mapping reveals about tumor recurrence
  
  
• How CIPI (Chemo-Immuno-Precision Injection) targets tumors directly
  
  
• Why precision oncology offers better outcomes with fewer side effects
  
  

📊 Precision oncology replaces guesswork with molecular-level accuracy — transforming how cancer is detected, treated, and prevented from coming back.

“False reassurance can be deadly. Precision testing finds what others miss.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493

What if your prostate cancer plan was just “shut down testosterone and hope for the best”?

That’s the reality for many patients — fatigue, weight gain, brain fog, and a life defined by side effects. In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, shares Bob’s story, a late-stage prostate cancer patient whose PSA was rising and bones were lighting up with metastases. Instead of following the same failing playbook, Bob chose precision oncology — and it changed everything.

Using deep mapping (DNA, RNA, immune profiling, and spatial biology), Dr. Prato’s team uncovered resistance markers and immune barriers that standard care missed. The result: a custom plan combining genetically targeted fractionated chemotherapy (GTF), direct-to-tumor chemo-immuno precision injection (CIPI), and immune reactivation through DAMP signaling. By restoring immune function and delivering therapy straight to the tumor, Bob’s PSA normalized, bone pain resolved, and his energy — and life — returned.

🎯 What You’ll Learn in This Episode:

• Why testosterone suppression alone fails many advanced prostate cancer patients

• The real difference between hormone blockade and immune-centered precision care

• How DNA, RNA, and spatial mapping reveal hidden cancer drivers

• The role of DAMPs in activating immune response and destroying cold tumors

• How GTF and CIPI deliver 100% precision targeting with 10% chemo dose

• Why precision oncology improves both outcomes and quality of life

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: https://www.envita.com
📞 Speak to a care coordinator: 866-830-4576

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493

When one patient’s cancer turned out to be two cancers in one — everything changed.

In this powerful episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, shares the story of Fran, a patient diagnosed with Stage IIIC ovarian cancer that revealed two mixed tumor types — low-grade serous and endometrioid carcinoma. After surgery and rising CA-125 levels, standard protocols called for more high-dose chemo, but Fran chose a smarter, more personalized path.

Dr. Prato walks through how his team used deep multi-omics testing (DNA, RNA, and spatial biology) to uncover multiple tumor drivers, hormone resistances, and immune barriers. By combining genetically targeted fractionated chemotherapy (GTF), adjuvant IV phytotherapeutics, and immune cell therapies built in-house, Envita was able to eliminate the cancer, restore energy, and achieve remission — all while strengthening the immune system.

🎯 What You’ll Learn in This Episode:

• How mixed-histology ovarian cancers behave differently from single-type tumors

• Why stromal barriers make traditional IV chemo less effective

• How microdosed, genetically targeted chemo activates immune killing

• The role of DNA, RNA, and immune profiling in mapping resistant pathways

• How phytotherapeutics (like curcumin and resveratrol) support immune repair

• Why precision monitoring of CA-125, methylation, and vesicle scores predicts outcomes

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: https://www.envita.com

📞 Speak to a care coordinator: 866-830-4576

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493

If you’ve been told to “eat whatever you want” during cancer treatment — that’s false advice.

In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, explains why food is treatment, not just fuel. The right diet can help starve cancer cells, repair DNA, detoxify the body, and rebuild immune strength during and after therapy. Based on 25 years of clinical experience, Dr. Prato shares the essential nutrition principles that help patients recover faster and respond better to precision oncology.

You’ll learn how to design a protein-centered, clean, and anti-inflammatory diet that supports energy, muscle recovery, and immunity — all while reducing sugar, refined carbohydrates, and toxic food exposure. From fasting during chemotherapy to rebuilding with antioxidants and micronutrients afterward, this is the roadmap to what Dr. Prato calls “gourmet immunity.”

🎯 What You’ll Learn in This Episode:

• How to reduce sugar and carbs to starve cancer cells safely

• The role of intermittent fasting in improving treatment response

• Why protein is the foundation for healing and muscle repair

• How to choose nutrient-dense, organic foods to support immunity

• The best healthy fats and antioxidants for detoxification

• How gut health, prayer, and stress reduction affect cancer recovery

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: https://www.envita.com
📞 Speak to a care coordinator: 866-830-4576

“Food isn’t just nutrition — it’s one of your strongest medicines.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493